1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsThis SBIR topic seeks to develop and demonstrate a universal, species-agnostic cell culture platform that enables rapid establishment of viable, reproducible cell lines from diverse non-model species and leverages autonomous, closed-loop culture automation.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Small business concerns (SBCs). Specific eligibility requirements for SBIR projects apply, including the PI being employed at least half-time by the awardee. Confirm the full requirements in the official notice before applying.
The current listing shows typical Phase I: $250,000; Typical Phase II: $1,800,000. Verify award ceilings, matching requirements, and allowable costs in the official notice.
DOD SBIR 2026.4 - Universal Cell Culture Platform for Rapid Establishment of Species-Agnostic Cell Lines and Autonomous Culture Operations is funded by DARPA, Biological Technologies Office. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
On June 3, 2026, four DARPA Biological Technologies Office SBIR topics close simultaneously — SWiFT, BARK, EXPOSITION, and Medical Swarm Robotics. Combined Phase I plus Phase II potential exceeds $6 million per company, and together they sketch a coherent strategy of distributed, autonomous, dual-species combat casualty care that depends on small businesses, not primes, to actually build.
Read articleDPA26BZ06-DV026 offers $300,000 at Phase I or $1,800,000 as a single Direct-to-Phase-II tranche with no options. The deliverable is a simulated auction market that measures whether AI agents deceive, collude, or manipulate the humans they serve — measured entirely from the outside. Here is the 90% efficiency gate, the team composition most bidders will get wrong, and why this topic sits in DARPA's biology office.
Read articleDARPA pre-released Release 6 of its FY26 SBIR BAA on September 2, 2026. Five of the seven SBIR topics belong to the Biological Technologies Office, and four of those describe one continuous problem: keeping a casualty alive with no surgeon, no imaging, and no evacuation. Here are the award sizes, the Direct-to-Phase-II gates, and the sequencing DARPA is buying.
Read article